INTERVENTION 1:	Intervention	0
Carotuximab (TRC105) Plus Capecitabine	Intervention	1
capecitabine	CHEBI:31348	26-38
All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)	Intervention	2
capecitabine	CHEBI:31348	31-43
capecitabine	CHEBI:31348	80-92
Inclusion Criteria:	Eligibility	0
Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only)	Eligibility	1
cancer	DOID:162	37-43
Histologically proven metastatic Her-2-negative breast cancer (Part 2 only)	Eligibility	2
breast cancer	DOID:1612	48-61
Measurable disease by RECIST 1.1 criteria (Part 2 only)	Eligibility	3
disease	DOID:4,OGMS:0000031	11-18
Willing and able to consent for self to participate in study	Eligibility	4
Progressive or recurrent disease after prior systemic chemotherapy regimen	Eligibility	5
progressive	HP:0003676	0-11
recurrent	HP:0031796	15-24
disease	DOID:4,OGMS:0000031	25-32
Age  18 years	Eligibility	6
age	PATO:0000011	0-3
ECOG performance status of 0 or 1	Eligibility	7
Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade  1 or baseline (except alopecia)	Eligibility	8
acute	HP:0011009,PATO:0000389	18-23
alopecia	HP:0001596,DOID:987	97-105
Adequate organ function	Eligibility	9
organ	UBERON:0000062	9-14
function	BAO:0003117,BFO:0000034	15-23
Exclusion Criteria:	Eligibility	10
Prior treatment with more than one systemic chemotherapy regimen for metastatic disease.	Eligibility	11
disease	DOID:4,OGMS:0000031	80-87
Prior treatment with TRC105	Eligibility	12
History of hypersensitivity reaction to antimetabolite therapy	Eligibility	13
history	BFO:0000182	0-7
hypersensitivity	GO:0002524,DOID:1205	11-27
antimetabolite	CHEBI:35221	40-54
Receipt of an investigational agent within 28 days of starting study treatment	Eligibility	14
Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment	Eligibility	15
surgery	OAE:0000067	6-13
Minor surgical procedures within 14 days prior to first dose of TRC105	Eligibility	16
History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease	Eligibility	17
history	BFO:0000182	0-7
brain	UBERON:0000955	11-16
brain	UBERON:0000955	102-107
spinal cord compression	HP:0002176	29-52
meningitis	HP:0001287,DOID:9471	71-81
disease	DOID:4,OGMS:0000031	126-133
Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months	Eligibility	18
congestive heart failure	HP:0001635,DOID:6000	24-48
transient ischemic attack	HP:0002326,DOID:224	76-101
pulmonary embolism	HP:0002204,DOID:9477	122-140
Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despite optimal therapy	Eligibility	19
chronic	HP:0011010	13-20
hypertension	HP:0000822,DOID:10763	21-33
Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia	Eligibility	20
past medical history	HP:0032443	0-20
hereditary hemorrhagic telangiectasia	DOID:1270	89-126
Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105	Eligibility	21
anticoagulant	CHEBI:50249	16-29
Cardiac dysrhythmias of NCI CTCAE Grade  2 within the last month	Eligibility	22
month	UO:0000035	59-64
Hemorrhage within 28 days of starting study treatment	Eligibility	23
Unhealed wounds within 28 days of starting study treatment	Eligibility	24
History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment	Eligibility	25
history	BFO:0000182	0-7
peptic ulcer disease	DOID:750	11-31
gastritis	HP:0005263,DOID:4029	35-44
condition	PDRO:0000129	94-103
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness	Eligibility	26
immunodeficiency	HP:0002721	12-28
immunodeficiency	HP:0002721	53-69
virus	BAO:0000232	29-34
acquired immunodeficiency syndrome	DOID:635	44-78
Known active viral or nonviral hepatitis	Eligibility	27
active	PATO:0002354	6-12
hepatitis	HP:0012115,DOID:2237	31-40
History of hypersensitivity reaction to human or mouse antibody products	Eligibility	28
history	BFO:0000182	0-7
hypersensitivity	GO:0002524,DOID:1205	11-27
antibody	GO:0042571,BAO:0000502	55-63
Lung cancer with central chest lesions	Eligibility	29
lung cancer	DOID:1324	0-11
central	HP:0030645	17-24
chest	UBERON:0001443	25-30
Pregnancy or breastfeeding	Eligibility	30
Outcome Measurement:	Results	0
Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine	Results	1
capecitabine	CHEBI:31348	63-75
Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1.	Results	2
Time frame: 1.5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Carotuximab (TRC105) Plus Capecitabine	Results	5
capecitabine	CHEBI:31348	43-55
Arm/Group Description: All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)	Results	6
capecitabine	CHEBI:31348	54-66
capecitabine	CHEBI:31348	103-115
Overall Number of Participants Analyzed: 6	Results	7
Measure Type: Count of Participants	Results	8
Unit of Measure: Participants  Patients with DLT at 7.5 mg/kg: 0   0.0%	Results	9
Patients without DLT at 7.5 mg/kg: 3  50.0%	Results	10
Patients with DLT at 10 mg/kg: 0   0.0%	Results	11
Patients without DLT at 10 mg/kg: 3  50.0%	Results	12
Adverse Events 1:	Adverse Events	0
Total: 6/19 (31.58%)	Adverse Events	1
Febrile neutropenia  [1]1/19 (5.26%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Fatigue  [1]1/19 (5.26%)	Adverse Events	3
fatigue	HP:0012378	0-7
Pyrexia  [1]1/19 (5.26%)	Adverse Events	4
Fracture  [1]1/19 (5.26%)	Adverse Events	5
Hip Fracture  [1]1/19 (5.26%)	Adverse Events	6
hip	UBERON:0001464	0-3
Headache  [2]1/19 (5.26%)	Adverse Events	7
headache	HP:0002315	0-8
